LungLife AI
Thousand Oaks
About LungLife AI
LungLife AI is a molecular diagnostics company that involves in the early detection and treatment of cancer. It uses machine learning and artificial intelligence to enable life-saving early diagnosis of lung cancer. The company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled the molecular analysis of cancer biomarkers in blood. The company is developing tests that span all stages of lung cancer from aid in diagnosis for patients with early-stage disease to treatment stratification and monitoring in late-stage lung cancer. The company's diagnostic technology combined with machine learning and image analysis results in workflow efficiencies and improvement in performance. It was founded in 2008 and is headquartered in Thousand Oaks, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $56.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2024)
- Ticker: lse:LLAI
- Website: lunglifeai.com
- Phone: +1 (805) 409-9868
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Diagnostics, Machine Learning, Medical
Social Profiles
Canonical: https://fsome.com/organization/lunglife-ai-129407 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.